AJ Velasquez-Mao

AJ Velasquez-Mao

Senior Associate atPivotal bioVenture PartnersSan Francisco Bay Area

AJ Velasquez-Mao is a senior associate at Pivotal bioVenture Partners, which invests at pre-seed, seed, series a, series b in life sciences, with checks of $3M to $30M.

What AJ can write

Writes checks of$3M to $30M
Comes in atPre-seed, Seed, Series A, Series BCan lead the round
Ownership target7-10%, 10-12%At first check
Pitch pageSubmit on their siteThe firm asks founders to apply here.

Pivotal bioVenture Partners writes $3M to $30M checks, larger than 93% of firms in the atlas.

Bars: how many firms report each check band. Highlighted: Pivotal bioVenture Partners.

Career

  1. Jefferies · equity research
  2. Dolby Family Ventures · early-stage therapeutics investor
  3. Pivotal bioVenture Partners · Sr Investment Associate
    Now

Focus

life sciencetherapeuticsbiotech

Education

UC Berkeley and UC San Francisco, PhD in BioengineeringRice University, BS in Bioengineering

Also at Pivotal bioVenture Partners

Partners like AJ

At firms with a similar stage, sector and check size.

Alert me when Pivotal bioVenture Partners is active

One email when AJ's firm raises a fund, adds a partner or shows new activity.

Founders and investors at a Mode VC gathering

Send Mode VC your deck

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.

Send your deck

Questions

Who is AJ Velasquez-Mao?

AJ Velasquez-Mao is a senior associate at Pivotal bioVenture Partners, which invests at pre-seed, seed, series a, series b in life sciences, with checks of $3M to $30M.

How much does AJ Velasquez-Mao invest?

AJ Velasquez-Mao invests through Pivotal bioVenture Partners, which writes checks of $3M to $30M at pre-seed, seed, series a, series b.

How do I pitch AJ Velasquez-Mao?

A warm intro from a founder Pivotal bioVenture Partners backed works best.

What did AJ Velasquez-Mao do before Pivotal bioVenture Partners?

equity research at Jefferies; early-stage therapeutics investor at Dolby Family Ventures.

Last updated 2026-10-15. Is this you? Ask for a correction.